343 related articles for article (PubMed ID: 11192100)
1. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia.
Cheffins T; Chan A; Haan EA; Ranieri E; Ryall RG; Keane RJ; Byron-Scott R; Scott H; Gjerde EM; Nguyen AM; Ford JH; Sykes S
BJOG; 2000 Dec; 107(12):1453-9. PubMed ID: 11192100
[TBL] [Abstract][Full Text] [Related]
2. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
Crossley JA; Aitken DA; Berry E; Connor JM
J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
[TBL] [Abstract][Full Text] [Related]
3. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
[TBL] [Abstract][Full Text] [Related]
4. Prenatal screening for Down's syndrome with use of maternal serum markers.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
[TBL] [Abstract][Full Text] [Related]
5. Selective miscarriage of Down's syndrome fetuses in women aged 35 years and older.
Macintosh MC; Wald NJ; Chard T; Hansen J; Mikkelsen M; Therkelsen AJ; Petersen GB; Lundsteen C
Br J Obstet Gynaecol; 1995 Oct; 102(10):798-801. PubMed ID: 7547736
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antenatal detection of Down's syndrome.
Wyllie JP; Madar RJ; Wright M; Burn J; Wren C
Arch Dis Child Fetal Neonatal Ed; 1997 Jan; 76(1):F26-30. PubMed ID: 9059182
[TBL] [Abstract][Full Text] [Related]
7. First trimester serum tests for Down's syndrome screening.
Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD011975. PubMed ID: 26617074
[TBL] [Abstract][Full Text] [Related]
8. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
Piggott M; Wilkinson P; Bennett J
J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
[TBL] [Abstract][Full Text] [Related]
9. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin.
Spencer K; Carpenter P
BMJ; 1993 Sep; 307(6907):764-9. PubMed ID: 7693095
[TBL] [Abstract][Full Text] [Related]
11. Screening of maternal serum for fetal Down's syndrome in the first trimester.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
[TBL] [Abstract][Full Text] [Related]
12. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study.
Ekelund CK; Jørgensen FS; Petersen OB; Sundberg K; Tabor A;
BMJ; 2008 Nov; 337():a2547. PubMed ID: 19039015
[TBL] [Abstract][Full Text] [Related]
13. Second trimester screening for Down's syndrome: 7 years experience.
Beaman JM; Goldie DJ
J Med Screen; 2001; 8(3):128-31. PubMed ID: 11678551
[TBL] [Abstract][Full Text] [Related]
14. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
Wald NJ; Kennard A; Densem JW; Cuckle HS; Chard T; Butler L
BMJ; 1992 Aug; 305(6850):391-4. PubMed ID: 1382768
[TBL] [Abstract][Full Text] [Related]
15. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
[TBL] [Abstract][Full Text] [Related]
16. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
17. Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free hCG subunit analyses.
Ryall RG; Staples AJ; Robertson EF; Pollard AC
Prenat Diagn; 1992 Apr; 12(4):251-61. PubMed ID: 1377388
[TBL] [Abstract][Full Text] [Related]
18. Gradual implementation of first trimester screening in a population with a prior screening strategy: population based cohort study.
Calda P; Sípek A; Gregor V
Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1029-33. PubMed ID: 20524903
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with the triple test for Down's syndrome screening.
Thornton JG; Cartmill RS; Williams J; Holding S; Lilford RJ
J Perinat Med; 1991; 19(3):151-4. PubMed ID: 1721090
[TBL] [Abstract][Full Text] [Related]
20. A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000.
Khoshnood B; De Vigan C; Vodovar V; Goujard J; Goffinet F
BJOG; 2004 May; 111(5):485-90. PubMed ID: 15104615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
